- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer ; volume:40 ; number:04 ; year:2019 ; pages:461-462
Indian journal of medical & paediatric oncology ; 40, Heft 04 (2019), 461-462
- Contributor
-
Noronha, Vanita
Mehta, Prashant
Malik, Prabhat Singh
Patel, Amol
- DOI
-
10.4103/ijmpo.ijmpo_210_19
- URN
-
urn:nbn:de:101:1-2021081213154754297764
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Noronha, Vanita
- Mehta, Prashant
- Malik, Prabhat Singh
- Patel, Amol
Other Objects (12)
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma